Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5556106 | 0.90 | CYP1A2 (0.40) | MALT1 | |
| SCHEMBL14453991 | 0.89 | ALDH1A1 (0.33) | MALT1EPAS1 | |
| SCHEMBL5562080 | 0.83 | CARM1 (0.31) | CARM1PRMT6 | |
| SCHEMBL5556124 | 0.83 | EPAS1 (0.38) | MALT1EPAS1CARM1PRMT6 | |
| SCHEMBL5556274 | 0.82 | CARM1 (0.39) | MALT1CARM1PRMT6 | |
| SCHEMBL5560997 | 0.81 | CYP1A2 (0.32) | — | |
| SCHEMBL5560864 | 0.80 | CYP1A2 (0.31) | EPAS1CARM1PRMT6 | |
| SCHEMBL5555325 | 0.80 | CYP1A2 (0.31) | CARM1PRMT6 | |
| SCHEMBL5556126 | 0.79 | CYP1A2 (0.31) | — | |
| SCHEMBL5561648 | 0.79 | EPAS1 (0.32) | EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1597235-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2007-08-15 | — | — | EP | disclosed |
| US-7241794-B2 | Nonnucleoside reverse transcriptase inhibitors | ROCHEPALO ALTO LLC (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241794-B2 | Nonnucleoside reverse transcriptase inhibitors | ROCHEPALO ALTO LLC (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1597235-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-23 | — | — | EP | disclosed |
| US-20040192666-A1 | Nonnucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2004-09-30 | — | — | US | disclosed |
| WO-2004074257-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192666-A1 | Nonnucleoside reverse transcriptase inhibitors | POLRMT, RRM2B, RRM2 | MALT1 1114/4885EPAS1 3601/4885CARM1 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.